Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...
Healio

Wegovy confers reductions in cardiovascular risk, regardless of weight loss

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...
Fierce Pharma

With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom meds

On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...

Bayer Wins FDA Approval for Menopause Drug Treating Hot Flashes

Bayer AG won support from US regulators for a menopause drug that’s expected to hit the market in November under the name of ...

US FDA approves Bayer's menopause relief drug

The U.S. Food and Drug Administration has approved Bayer's drug to ease hot flashes in menopausal women, the German company ...